Our Science Team, led by IMPRODIA includes some of the leading scientists in the field. These experts contribute to our efforts, giving us a depth of knowledge in this complex field.
Tuvia Sofinzon, BSc, MBA
Chief Executive Officer
Tuvia has served as Chief Executive Officer and director of ImProDia since 2012. Tuvia has more than 30 years of experience in the medical business in Europe and Israel in which he managed companies taking them throughout all stages from development to product marketing. Prior to joining ImProDia he served as CEO and Founder of European activities at DIREX SYSTEMS S.A., Paris, France. Tuvia holds a B.Sc in Electrical Engineering from the Technion and MBA from Pace University, New York.
Michal Baniyash, PhD
Chief Science Officer
Michal received her Ph.D. in Immunology from the Weizmann Institute of Science. She performed her Post-doctorate studies at the NIH, Bethesda, USA and currently, she is an Associate Professor in immunology and a group leader at the Lautenberg Center for Tumor and General Immunology, Hadassah Medical School, The Hebrew University, Jerusalem. Michal has more than 20 years of experience in conducting pioneering research with her team. She has a number of prestigious publications and numerous inventions on the field of Biomarkers. Michal holds M.Sc in Microbiology and a B.Sc. from Tel-Aviv University.
Raphael Nir, PhD
Chief Operation Officer
Raphael received his Ph.D. in Biotechnology from Tel-Aviv University. He has 20 years of experience in the field of recombinant protein production and related processes. Raphael is the President and the co-Founder of SBH Sciences and the Director of Process Development at Neumedicines.
Yair Klieger, PhD
Chief Technology Officer
Yair received his Ph.D. in Immunology from the Hebrew University, Jerusalem where he performed his studies at the Lautenberg Center for Tumor and General Immunology in the laboratory of Professor Baniyash focusing on the relationship between chronic inflammation and the revolutionary CD247 biomarker expression and function. Before his Ph.D. studies, Yair served as an operation manager in the start-up company Wi-Tech Ltd. Yair holds a M.Sc. in Biotechnology and a B.Sc. from the Hebrew University.
Eliran ish Shalom, PhD
Eliran received his Ph.D. in Immunology from the Hebrew University, Jerusalem where he performed his studies at the Lautenberg Center for Tumor and General Immunology in the laboratory of Professor Baniyash focusing on defining the relation between chronic inflammation and new biomarke’s expression. Eliran holds a M.Sc. in Biotechnology from the Hebrew University and a B.Sc. from Tel-Hai College.